Development of Extragenital Lichen Sclerosus in Malignant Melanoma Patients Treated With Ipilimumab in Combination With Nivolumab.

Seyed Jafari, S. Morteza; Feldmeyer, Laurence; Hunger, Robert E. (2020). Development of Extragenital Lichen Sclerosus in Malignant Melanoma Patients Treated With Ipilimumab in Combination With Nivolumab. Frontiers in oncology, 10, p. 573527. Frontiers Research Foundation 10.3389/fonc.2020.573527

[img]
Preview
Text
fonc-10-573527.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (466kB) | Preview

The immune checkpoint inhibitors opened a new era for the treatment of melanoma. Nowadays, combined immune checkpoint inhibitors are administered to provide additive or synergistic effects on anti-melanoma immunity. The use of these drugs comes with serious adverse events related to excessive immune activation. Here, we present development of extragenital lichen sclerosus in a patient with metastatic malignant melanoma, during the combined therapy with checkpoint inhibitors.

Item Type:

Journal Article (Further Contribution)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Dermatology

UniBE Contributor:

Jafari, Morteza; Feldmeyer, Laurence and Hunger, Robert

Subjects:

600 Technology > 610 Medicine & health

ISSN:

2234-943X

Publisher:

Frontiers Research Foundation

Language:

English

Submitter:

Sandra Nyffenegger

Date Deposited:

10 Dec 2020 13:48

Last Modified:

24 Feb 2021 00:00

Publisher DOI:

10.3389/fonc.2020.573527

PubMed ID:

33117707

Uncontrolled Keywords:

checkpoint inhibitors extragenital lichen sclerosus et atrophicus ipilimumab malignant melanoma metastatic nivolumab

BORIS DOI:

10.7892/boris.148365

URI:

https://boris.unibe.ch/id/eprint/148365

Actions (login required)

Edit item Edit item
Provide Feedback